# Veru Inc. (VERU)

> Veru Inc. (VERU) trades at $2.14 (+2.88%) as of 7:30:01 PM EST on Nov 17, 2026, -7.36% over the past month. Market cap is $35.46M, with 13.3 days to cover in short interest.

Canonical: https://massive.com/quote/veru
Data as of: 2026-11-18T00:30:01.810Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$2.14** +0.06 (+2.88%)
As of 7:30:01 PM EST on Nov 17, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Veru Inc. (VERU) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.88% |
| 1W | +0.94% |
| 1M | -7.36% |
| YTD | +0.00% |
| 1Y | -15.42% |
| 52-wk range | $2.03 – $7.33 |

From daily closes through Nov 17, 2026.

## Key statistics

Today's trading snapshot for VERU: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $2.07 – $2.20 |
| Open | $2.09 |
| Prev close | $2.08 |
| Volume | 305K |
| Market cap | $35.46M |
| Shares out | 17.05M |

## Valuation and profitability ratios

Valuation and profitability ratios for Veru Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 1.25 |
| P/FCF | — |
| ROE | -48.0% |
| ROA | -36.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 16, 2026

## Insider trading

[Veru Inc. (VERU) insider trading](https://massive.com/quote/veru/insider-trading.md): open-market Form 4 buys and sells by Veru Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Veru Inc. has disclosed to the SEC on Form 8-K.

- Sep 8, 2026 · Strategic initiative
  “The Company has made the strategic decision to expand its current drug development pipeline to advance sabizabulin as a potential novel treatment for patients whose metastatic pancreatic cancer has become resistant to daraxonrasib.”
- Jul 2, 2026 · Underwriting agreement
  “The Company will pay the Designated Sales Agent a commission of 3.0% of the aggregate gross proceeds from each sale of the Common Stock and has agreed to provide the Sales Agents with customary indemnification and contribution rights, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.”
- Jun 4, 2026 · Partnership or collaboration
  “On June 2, 2026, Veru Inc. (the "Company") entered into a clinical supply agreement (the "Supply Agreement") with Novo Nordisk A/S ("Novo Nordisk") in conjunction with the Company's Phase 2b PLATEAU clinical study. Under the terms of the Supply Agreement, the Company is solely responsible for conducting and sponsoring the Phase 2b PLATEAU clinical study while Novo Nordisk will supply Wegovy® to the Company at no charge and as required for the conduct of the Phase 2b PLATEAU study.”
- Oct 30, 2025 · Underwriting agreement
  “On October 30, 2025, Veru Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Canaccord Genuity LLC, as representative of the underwriters named therein (the "Underwriters"), relating to the offering, issuance and sale (the "Offering") of 8,400,000 shares of the Company's common stock...at a combined public offering price of $3.00 per Share and accompanying Series A Warrant and Series B Warrant.”
- Sep 26, 2025 · Settlement agreement
  “On September 22, 2025, the Company and the Borrower entered into a Settlement Agreement and Release (the 'Settlement Agreement'), whereby the Company agreed to accept a cash payment of $6,326,155.41, 3,125 shares of the Borrower's Series D Convertible Preferred Stock and 846,975 warrants to purchase shares of the Borrower's common stock in full satisfaction of all amounts due under the Promissory Notes.”

## Dividend history and stock splits

Veru Inc.'s recent dividend payments and stock splits.

### Dividends

- $0.07 · ex-div Apr 28, 2014
- $0.07 · ex-div Jan 27, 2014
- $0.07 · ex-div Oct 28, 2013
- $0.07 · ex-div Jul 29, 2013

### Splits

- 1-for-10 · Aug 11, 2025

## VERU short interest

How heavily VERU is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 13.3 |
| Short interest | 1.5M |
| Avg volume | 113.11K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## VERU news

The latest news and headlines about Veru Inc. (VERU).

- [Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline](https://www.benzinga.com/news/asset-sales/24/12/42744301/veru-sells-fc2-condom-business-for-18-million-focuses-on-biopharma-pipeline) · Benzinga · Dec 31, 2024 · positive sentiment
- [Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business](https://www.globenewswire.com/news-release/2024/12/31/3003127/11676/en/Veru-Announces-the-Sale-of-the-FC2-Female-Condom-Internal-Condom-Business.html) · GlobeNewswire Inc. · Dec 31, 2024 · positive sentiment
- [Sexual Wellness Market to Witness 4.7% CAGR by 2031 \| SkyQuest Technology](https://www.benzinga.com/pressreleases/24/10/g41162776/sexual-wellness-market-to-witness-4-7-cagr-by-2031-skyquest-technology) · Benzinga · Oct 3, 2024 · positive sentiment
- [Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism](https://www.globenewswire.com/news-release/2024/07/02/2907391/11676/en/Veru-to-Participate-in-the-Leerink-Therapeutics-Forum-I-I-and-Metabolism.html) · GlobeNewswire Inc. · Jul 2, 2024
- [Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions](https://www.globenewswire.com/news-release/2024/06/24/2902971/11676/en/Veru-Announces-Safety-and-Body-Composition-Data-from-Two-Late-Breaker-Presentations-at-the-American-Diabetes-Association-s-84th-Scientific-Sessions.html) · GlobeNewswire Inc. · Jun 24, 2024

## About Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Listed | Jun 1, 1990 |

[Company website](https://www.verupharma.com)

## FAQ

### What is the Veru Inc. (VERU) stock price today?

Veru Inc. (VERU) is trading at $2.14 (+2.88% on the day) as of 7:30:01 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Veru Inc.?

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin.

### What is the short interest in VERU?

As of Oct 30, 2026, VERU has 1.5M shares short and 13.3 days to cover.

### Does Veru Inc. (VERU) pay a dividend?

Yes. Veru Inc. (VERU)'s most recent dividend was $0.07 per share, with an ex-dividend date of Apr 28, 2014. Full VERU dividend history is available from the Massive API.

### What exchange is VERU listed on?

Veru Inc. (VERU) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time VERU quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=VERU`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Veru Inc. (VERU) insider trading](https://massive.com/quote/veru/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
